Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

Teru Hideshima¹, Ralph Mazitschek², Jun Qi¹, Naoya Mimura^1,5, Jen-Chieh Tseng^3,6, Andrew L. Kung^3,4,7, James E. Bradner^1,8 and Kenneth C. Anderson¹

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
² Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
³ Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, USA
⁴ Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children’s Hospital Boston, Boston, MA, USA
⁵ Department of Hematology, Chiba University Hospital, Chiba, Japan
⁶ PerkinElmer Inc., Hopkinton, MA, USA
⁷ Memorial Sloan Kettering Cancer Center, New York, NY, USA
⁸ Novartis Institutes for BioMedical Research, Cambridge, MA, USA

Published: August 17, 2021

This article has been corrected: The CONFLICTS OF INTERESTS section has been updated as shown below:

CONFLICTS OF INTEREST

K.C. Anderson is on the advisory board of Celgene, Gilead, Millennium and Bristol Myers Squibb; and is a scientific founder with financial interest in Acetylon, Oncopep and C4 Therapeutics. JB is a scientific founder with financial interest in Acetylon.

Original article: Oncotarget. 2017; 8:80109–80123. DOI: https://doi.org/10.18632/oncotarget.19019.